Navigation Links
DOR BioPharma Receives FDA Orphan Drug Designation for orBec(R) for the Treatment of Chronic Gastrointestinal GVHD
Date:8/4/2009

PRINCETON, N.J., Aug. 4 /PRNewswire-FirstCall/ -- DOR BioPharma, Inc., (OTC Bulletin Board: DORB) (DOR or the Company), a late-stage biopharmaceutical company, announced today that the Office of Orphan Products Development of the United States Food and Drug Administration (FDA) has granted Orphan Drug Designation to Oral BDP (beclomethasone 17,21-dipropionate, or orBec((R))) for the treatment of gastrointestinal symptoms associated with chronic Graft-versus-Host disease (cGVHD) in patients who have undergone allogeneic hematopoietic cell transplantation.

The US Orphan Drug Act is intended to assist and encourage companies to develop safe and effective therapies for the treatment of rare diseases and disorders. In addition to providing a seven-year term of market exclusivity for orBec((R) )upon final FDA approval, orphan drug designation also positions DOR to be able to take advantage of a wide range of financial and regulatory benefits, including government grants for conducting clinical trials, waiver of expensive FDA user fees for the potential submission of a New Drug Application for orBec((R)), and certain tax credits.

orBec((R) )is a highly potent, topically active corticosteroid that has a local effect on inflamed tissue. BDP, the active component of orBec((R)), has been marketed in the United States and worldwide since the early 1970s as the active pharmaceutical ingredient in inhalation products for the treatment of patients with allergic rhinitis and asthma. orBec((R)) and oral BDP are currently in development by DOR for the treatment and prevention of GVHD, the prevention of acute radiation enteritis and the treatment of Crohn's disease.

"The FDA's decision to grant orBec((R)) Orphan Drug Designation for the treatment of GI symptoms of cGVHD marks another step in the expansion of our orBec((R))/oral BDP pipeline," stated Christopher J. Schaber, PhD, President and CEO of DOR Bio
'/>"/>

SOURCE DOR BioPharma, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. China Biopharmaceuticals Holdings Announces Second Quarter 2007 Financial Results
2. XTL Biopharmaceuticals Announces Financial Results for the Six Months Ended June 30, 2007
3. PDL BioPharma Announces Internal CEO Investigation Found No Credible Evidence of Improper Personal Conduct or Breach of Fiduciary Duty
4. Nabi Biopharmaceuticals to Present at Upcoming Industry Conferences
5. PDL BioPharma Announces Significant Strategic and Portfolio Changes to Focus on Antibody Discovery and Development
6. XTL Biopharmaceuticals Announces Presentation of Novel Pre-Clinical Inhibitors of Hepatitis C at an Upcoming International Scientific Conference
7. XTL Biopharmaceuticals Initiates Phase IIb Clinical Trial of Bicifadine for the Treatment of Diabetic Neuropathic Pain
8. Nabi Biopharmaceuticals Announces Sale of Nabi Biologics to Biotest AG
9. Keryx Biopharmaceuticals to Present at Bank of America Investment Conference
10. Morria Biopharmaceuticals Plc Announces Appointment of Dr. Rosemary Mazanet as Interim Chief Executive Officer
11. Keryx Biopharmaceuticals, Inc. Announces Appointment of Michael P. Tarnok to Board of Directors
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... RedBrick Health , a fast-growing leader in consumer health ... EmblemHealth , the New York -based ... RedBrick Compass health assessment, combined with the RedBrick Journeys ... EmblemHealth is among the first health plans in the ...
(Date:1/15/2014)... TX (PRWEB) January 15, 2014 More ... disease, and about 1 in 3 seniors will die ... source ). These jaw-dropping figures have shocked many Americans ... and, hopefully, help prevent these tragic age-related cognitive disorders. ...
(Date:1/15/2014)... DTS Language Services, Inc . is pleased to ... Science organizations who need document translations. Clients will now ... documents in advance with a selection of nearly 50 life ... a critical factor in clinical and scientific fields, and decrease ...
(Date:1/15/2014)... (PRWEB) January 15, 2014 AudioNotch is ... new therapy for the treatment of tinnitus. Patients listen ... frequency, and over a period of weeks to months, their ... Therapy in two forms: Notched Music and Notched White Noise. ...
Breaking Biology Technology:EmblemHealth Selects RedBrick Health to Power its Next-Generation Health Engagement and Behavior Change System 2EmblemHealth Selects RedBrick Health to Power its Next-Generation Health Engagement and Behavior Change System 3Biohack Pure Offers 5 Tips for Increasing Memory in 2014 2DTS Improves Efficiency for Life Science Document Translations 2
... a leading clinical stage biotechnology company with offices ... proprietary stem cell and tissue engineering based therapies, ... Cooperative Research and Development Agreement (CRADA) with the ... at Fort Sam Houston, Texas. The 3-year CRADA, ...
... PARK, Md., June 6, 2011 CosmosID™, a ... (TAP) incubator developing comprehensive pathogen identification technologies, ... life sciences company category during the 2011 Maryland ... (Logo: http://photos.prnewswire.com/prnh/20101005/MTECHLOGO ) In ...
... June 6, 2011 Celtaxsys, Inc., a private biopharmaceutical company ... sciences industry veteran, H. Daniel Perez, M.D., to its Board ... Dr. Perez has joined the Celtaxsys team," says Dr. Michael ... "He brings more than 25 years of high level pharmaceutical ...
Cached Biology Technology:Arteriocyte and the U.S. Army Institute of Surgical Research (USAISR) Sign a CRADA to Speed Development of Cellular Therapies for Orthopaedic Trauma 2Arteriocyte and the U.S. Army Institute of Surgical Research (USAISR) Sign a CRADA to Speed Development of Cellular Therapies for Orthopaedic Trauma 3Mtech TAP Company CosmosID™ Wins Best Life Sciences Company in the Maryland Incubator Company of the Year Awards 2Mtech TAP Company CosmosID™ Wins Best Life Sciences Company in the Maryland Incubator Company of the Year Awards 3Mtech TAP Company CosmosID™ Wins Best Life Sciences Company in the Maryland Incubator Company of the Year Awards 4Dr. H. Daniel Perez Joins Celtaxsys Board of Directors 2
(Date:7/10/2014)... 10 July 2014 Amyloid diseases, such as ... spongiform encephalopathies, all share the common trait that ... plaques. Yet in vitro studies have found that ... themselves are very toxic. New evidence using two-dimensional ... structure during the amylin aggregation pathway that may ...
(Date:7/10/2014)... 10,2014 For children and teens living with a ... contribute to decreased quality of life, reports a study ... Behavioral Pediatrics , the official journal of the ... The journal is published by Lippincott Williams & ... . , "Self-competence may function as a protective factor ...
(Date:7/10/2014)... natural-color satellite image was collected by the Moderate Resolution ... 10, 2014. Each hot spot, which appears as a ... on the MODIS instrument recognized temperatures higher than background. ... image, such hot spots are diagnostic for fire. ... little danger coming directly from the fires, although the ...
Breaking Biology News(10 mins):New technology reveals insights into mechanisms underlying amyloid diseases 2For children with pacemakers, 'self-competence' affects quality of life 2
... appointment of Esin Gulari, dean of the College of Engineering ... Science Board (NSB). President George W. Bush nominated Gulari for ... is a tremendous honor for me as a scientist and ... in a unique position to make contributions on a national ...
... 3, 2008 Case Western Reserve University School of Medicine ... The National Children,s Study, the National Institutes of Health,s comprehensive ... children,s health. At a briefing today, NIH ... one of 36 new and existing study centers which would ...
... observance of Nuclear Medicine Week (October 5 to 11) ... today a new fact sheet highlighting recent developments in ... in which breast cancer is diagnosed and treated. ... painless imaging tool for diagnosing and treating breast cancer. ...
Cached Biology News:US Senate confirms Clemson University engineering Dean Esin Gulari to National Science Board 2NIH selects Case Western Reserve University to participate in National Children's Study 2SNM releases new fact sheet on breast cancer and molecular imaging 2
Alkali soluble casein is the recommended blot blocking reagent for use with the HisTag Monoclonal Antibody (Novagen) on Western blots....
Anti-Human Factor XI Purified (Polyclonal) (sheep IgG)...
Rad51B...
Ku80 Antibody Shipping Temperature: HOT Storage Temperature: -20C...
Biology Products: